Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy
An erratum to this article was published (Osteoporos Int, Jun 2024 ↗)
Authors' conclusion
BMD may serve as a novel early indicating marker for monitoring bone fragility for DMD.
Study context
- Population
- Young ambulatory boys with Duchenne muscular dystrophy (DMD) treated with glucocorticoid (GC), West China Second University Hospital (2016–2023)71 with >3 bone mineral density (BMD) records
- Participants
- 153 participants
- Outcome
- BMD progression pattern (trajectories) and risk markers for bone loss
Methodological detailslongitudinal, group-based trajectory modelling, logistic regression and survival analysis
- Longitudinal
- Group-based trajectory modelling
- Logistic regression and survival analysis
Main finding
As reported in the abstract
BMD trajectories
- Three BMD trajectories identified
- 3
- Median survival time to first observation of low BMD (years)
- 5.32 (95% CI 4.05-6.59)
- Difference in time to low BMD among the three trajectory groups
- P < 0.001
Observational data: associations, not effects.
Original publication
Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy. Osteoporos Int. Published 26 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →